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Abstract
OBTECTIVE: To explore the role of transient re-
ceptor potential vanilloid subetype 1 (TRPV1) in
the increase of the thermal pain threshold by
moxibustion.
METHODS: Forty Kunming mice (20 ± 2) g were
randomized into control group,capsaicin group,
capsazepine group, moxibustion group and moxi-
bustion + capsazepine (MC) group with 8 mice in
each, and 16 C57BL/6 wild-type mice (18 ± 2) g
were randomized into wild-type (WT) control
group and WT moxibustion group with 8 mice in
each, and 14 TRPV1 knockout mice (18 ± 2) g were
randomized into knockout (KO) control group and
KO moxibustion group with 7 in each. Each mouse
in the capsaicin group was subcutaneously inject-
ed with the amount of 0.1 mL/10 g into L5 and L6
spinal cords; each mouse in the capsazepine group
was intraperitoneally injected with the amount of
0.1 mL/10 g. Similarly, each mouse in the moxibus-
tion group was given a suspended moxibustion
with specially-mademoxa-stick for 20min on L5 and
L6 spinal cords. Each mouse in MC group was intra-
peritoneally injectedwith the amount of 0.1mL/10 g
first, then after 15 min was given a suspended mox-
ibustion for 20 min on L5 and L6 spinal cords. Each
mouse in WT moxibustion group and KO moxibus-
tion group was given a suspended moxibustion
with specially-made moxa-stick for 20 min on L5
and L6 spinal cords. The control group, WT control
group and KO control group were of no treatment
in any way. After all treatments were completed, the
digital-display measurement instrument for thermal
pain was used to measure the threshold of thermal
pain in each group respectively.
RESULTS: Compared with the control group, the
thresholds of thermal pain in the moxibustion
group and MC group were significantly increased
(P <0.01); no significant changes in the thresholds
in the capsaicin group and the capsazepine group
(P > 0.05); compared with moxibustion group, he
threshold of thermal in MC group was obviously de-
creased (P < 0.01). Compared with WT control
group, the threshold of thermal pain in WT moxi-
bustion group was significantly increased (P <
0.01); compared with KO control group, no changes
in the threshold in KOmoxibustion group (P > 0.05).
CONCLUSION: TRPV1 participated in the process of
increasing the threshold of thermal pain by stimu-
lating L5 and L6 of mice spinal cord with burning
mosa-stick.
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INTRODUCTION
The transient receptor potential vanilloid (TRPV) 1 re-
ceptor is a nonselective cation channel, which is ex-
pressed on peripheral and central terminals of small
and mediumsized primary sensory neurons.1 Since the
receptor could be activated by capsaicin of specificity,
it is also known as capsaicin receptor,2 which could also
be activated by a wide range of noxious stimulations in-
cluding protons and heat etc. When the temperature is
higher than 43 ℃, TRPV1 will be activated as is recog-
nised as one of the thermo-sensitive cation channels.3
TRPV1 can also be sensitized by different stimulations,1
and its sensitization is crucial in the development of
pain,4 which is an important property of pain signaling,5
playing a key role in pain transmission and modula-
tion.6 Under certain nerve injury or inflammatory dis-
ease conditions, TRPV1 is up-regulated.7 TRPV1 is a
noxious signaling, which becomes the potential thera-
peutic target for developing analgesics.4 Many studies
show that, the expression of TRPV1 could be inhibited
by virtue of TRPV1 antagonist to attenuate pain and
heat hyperalgesia.8-11 However, topical application of
capsaicin is clinically effective in treating a variety of
chronic painful conditions, including postherpetic neu-
ralgia and HIV-associated peripheral neuropathies. Its
analgesic action is considered a consequence of inhibi-
tion of TRPV1 function by desensitization.7
Moxibustion therapy is an important part of the acu-
puncture and moxibustion therapy in Traditional Chi-
nese Medicine. It is a kind of external treatment using
folium artemisiae argyi or moxa as the principal materi-
al to cauterize or warm and iron at the acupoint or dis-
eased region on body surface after ignition for the pur-
pose of prevention, healthcare and cure. The heat stim-
ulation of ignited moxa will directly or indirectly ef-
fects at specific areas of human body surface, generate
effects on local and distant regions through meridians,
and it is also the key property and the one of the causes
for curative effect.12 Pain relief is one of the main ef-
fects of moxibustion therapy12 which has been existed
for over two thousand years with a wide range of indi-
cations, applicable for deficiency, excess and acute dis-
eases.13 There is a research shown that, moxibustion
may increase the expressions of POMC mRNA and
PDYN mRNA in hypothalamus of rats,as well as pro-
mote the analgesic potency of organism, suggesting the
moxibustion has analgesic effect.14
TRPV1 is a temperature sensor which is a member of
the TRP family, and may be in connection with the ac-
tivation mechanism of warming and promoting effect
from moxibustion. TRPV1 can be activated by heat
stimulation of > 43 ℃ , which is similar to the local
skin temperature caused by moxibustion.15 TRPV1
plays a basic role in the signal transduction of tissue in-
juries and pain reponses, regaeding the analgesic effect
of moxibustion, therefore, whether TRPV1 partici-
pates in the analgesic process of moxibustion heat ef-
fect? This study shall try to discuss the role of TRPV1
in the increase of the thermal pain threshold by moxi-
bustion.
MATERIALS ANDMETHODS
Experimental animals
Fifty Kunming (KM) male mice of 18-22g (Certificate
No. of SCXK (Shanghai): 2007-0005, provided by
Shanghai Slac Laboratory Animal Co., Ltd.,), 24
C57BL/6 wild-type male mice of 16-20 g [Certificate
No. of SCXK (Jiangsu): 2010-0001, provided by Labo-
ratory Animal Center of Nanjing University], and 21
J003770 TRPV1 knockout male mice of 17-20 g [Cer-
tificate No. SCXK (Jiangsu): 2010-0001, provided by
Laboratory Animal Center of Nanjing University].
Reagent preparation
Capsaicin (50 mg),Capsazepine (25 mg), 500 mL abso-
lute ethyl alcohol, Polyoxyethylene Sorbitan (Tween
80) (500 mL) and Dimethyl Sulfoxide (50 mL) were
purchased from Sigma (St. Louis, MO, USA). Normal
Saline (250 mL) was purchased from Guangdong Litai
pharmaceutical Limited by Share Ltd. (Guangdong,
China). Capsaicin in powder 50mg is dissolved in 10%
polyoxyethylene sorbitan (Tween 80) and 10% ethanol
before being mixed with 80% normal saline to obtain a
capsaicin solution of 0.01 M;16 Capsazepine in powder
25 mg is dissolved in 25 mL dimethyl sulphoxide and
then diluted in normal saline to obtain a capsazepine
solution of 0.01 M.17
Experimental apparatus
JL-F Digital-display type measurement instrument for
thermal pain was purchased from Shanghai Precision
Instrument Co., Ltd., (Shanghai, China), Special-made
moxa-stick (5 mm × 200 mm) was purchased from
Nanyang Hanyi Moxibustion Technology Develop-
ment Co., Ltd., (Nanyang, China), 1 mL Disposable
sterilized syringe was purchased from Changzhou Med-
ical Appliances General Factory Co., Ltd., (Chang-
zhou, China)
ExperimentⅠ
Grouping: 40 KM mice (20 ± 2) g are randomized into
5 groups by random number table method: control
group, capsaicin group, capsazepine group, moxibus-
tion group and moxibustion+capsazepine (MC) group
with 8 mice in each, and the rest 10 mice are backups
without any treatment.
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Group treatment: Each mouse in the capsaicin group is
subcutaneously injected with the amount of 0.1 mL/
10 g into the L5, L6 spinal cords;18 Each mouse in the
capsazepine group is intraperitoneally injected with the
amount of 0.1 mL/10 g. Similarly, each mouse in the
moxibustion group is given a suspended moxibustion
with specially-made moxa-stick for 20 min on L5 and
L6 spinal cords. Each mouse in MC group is intraperi-
toneally injected with the amount of 0.1 mL/10 g first,
then after 15 min is given a suspended moxibustion for
20 min on L5 and L6 spinal cords. The control group
was of no treatment in any way.
Pain threshold measurement: after all treatments are
completed, use the digital-display measurement instru-
ment for thermal pain to respectively measure the
threshold of thermal pain in each group. Record the
displaying value on the instrument when the tails of
mice go up for heat.
ExperimentⅡ
Grouping: 16 C57BL/6 wild-type mice [(18 ± 2) g] are
randomized into 2 groups by random number table
method: wild-type (WT) control group and WT moxi-
bustion group with 8 in each and the rest 8 are back-
ups without any treatment. 14 TRPV1 knockout mice
[(18 ± 2) g] are randomized into 2 groups by random
number table method: knockout (KO) control group
and KO moxibustion group with 7 in each and the rest
7 are backups without any treatment.
Group treatment: each mouse in WT moxibustion
group and KO moxibustion group is given a suspended
moxibustion with specially-made moxa-stick for 20 min
on L5 and L6 spinal cords. The WT control group and
KO control group are of no treatment in any way.
Pain threshold measurement: After all treatments were
completed, the digital-display measurement instru-
ment for thermal pain was used to measure the thresh-
old of thermal pain in each group respectively.
Data analysis
All data were presented as mean ± standard deviation
statistics, tested by one-way analysis of variance, analy-
sis with SPSS 17.0 (SPSS, Chicago, IL, USA). P < 0.05
was considered statistically significant.
RESULTS
The digital-display measurement instrument for ther-
mal pain presents the threshold level in the length of
time it recorded. The higher of heat tolerance, the lon-
ger of the time recorded, indicating the higher thresh-
old and larger threshold value of thermal pain. In our
study, tail-flick time(s) of mice was taken as the value
of thermal pain threshold.
Comparison of threshold of thermal pain for KM
mice among the groups
In experiment Ⅰ, compared with the control group
[(15.4 ± 4.5) s], no significant changes in the thermal
pain thresholds in the capsaicin group [(12.7 ± 2.8) s]
and the capsazepine group [(16.7 ± 2.6) s] (P > 0.05),
which was of the similar levels with the control group.
The thermal pain threshold in the moxibustion group
[(44.3 ± 6.5 s)] and MC group [(31.6 ± 2.4) s] were
significantly increased (P <0.01); compared with the
moxibustion group [(44.3 ± 6.5) s], the threshold in
MC group [(31.6 ± 2.4) s] was obviously decreased
with significance (P < 0.01), indicating moxibustion
played a role in increasing the thermal pain threshold,
while capsazepine might play the role of partial antago-
nism against the analgesic effect of moxibustion.
Comparison of threshold of thermal pain of mice in
wild-type groups and TRPV1 knockout groups
In Experiment Ⅱ, compared with WT control group
[(16.7 ± 2.5) s], the thermal pain threshold in WT
moxibustion group [(49.1 ± 8.6) s] had been increased
significantly (P < 0.01); compared with KO control
group [(53.1 ± 9.3) s], no changes in the threshold in
KO moxibustion group [(54.0 ± 9.6) s] (P > 0.05), sug-
gesting that TRPV1 knockout mice is less sensitive to
noxious heat stimulation,with threshold of thermal
pain not obviously changed, which means TRPV1 was
essential element in causing hyperalgesia responses to
noxious thermal stimulation.
DISCUSSION
Pain is the instantaneous unpleasant sensation subse-
quent to a noxious or potentially injurious stimulus, as
a warning system for tissue protection against inju-
ries.19 "Pain Threshold" refers to the minimum amount
of stimulations causing pain, which is widely used as
the indicator for measuring analgesic effect14 that, the
higher of threshold of pain, the better the analgesic ef-
fect shall be, conversely, the lower the threshold of
pain, the poorer the analgesic effect.
TRPV1 is a member of the transient receptor potential
family, which is a heat- sensitive ligand-gated Ca2+ -per-
meable ion channel.4 TRPV1 channels are found
throughout the body in epithelial cells and in peripher-
al and central terminals in neurons that can be activat-
ed by capsaicin, low pH, proton and heat stimulation
of > 43℃. TRPV1,a noxious stimuli molecular integra-
tor, exerts variety of functions ranging from nocicep-
tion and pain.20 Hence TRPV1 is regarded as the most
hopeful therapeutic target in pain treatment.
Moxibustion therapy is an important part of the acu-
puncture and moxibustion therapy in Traditional Chi-
nese Medicine, and a kind of external treatment for the
purpose of prevention, healthcare and cure. Moxibus-
tion therapy is capable of curing pain that, the heat
stimulation of moxibustion might be the premise and
foundation of analgesic effect playing.14
Our study has found that the threshold of thermal
pain in the moxibustion group was significantly in-
creased compared with it in the control group, suggest-
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ing that moxibustion was capable of increasing the
thermal pain threshold. The threshold of thermal pain
in the WT moxibustion group was significantly in-
creased compared with it in the WT control group;
and no significant difference was found between the
threshold of thermal pain in the KO moxibustion
group and it in the KO control group, which is consis-
tent with the study results of predecessors. The
wild-type mice exhibited decreased thresholds or laten-
cies of withdrawal in response to thermal stimuli, in
contrast, mice lacking functional TRPV1 only dis-
played less sensitive to painful thermal stimuli.5 After
heat stimulation of moxibustion, the thermal pain
threshold in WT moxibustion group is increased signif-
icantly, while no changes in it of the KO moxibustion
group. It could be concluded from the above results
that, the moxibustion increasing threshold of thermal
pain is correlative to TRPV1.
Previous studies have shown that after a long-time or
high-dose administration of TRPV1 agonist, the ther-
mal pain threshold could be increased, thus generating
an analgesic effect,21 whereas a single administration of
lower doses may cause activation of TRPV1.22 In this
experiment, the thermal pain threshold of capsaicin
group was slightly decreased compared with it of the
control group, indicating that capsaicin played no role
in increasing the thermal pain threshold. The reason
might be the single administration of capsaicin via lo-
cal subcutaneous injection in capsaicin group was in a
lower dose thereby activating TRPV1 causing decrease
of the threshold; while the longer time of heat stimula-
tion increased the threshold in the moxibustion group.
Single administration of capsazepine is incapable of in-
creasing the thermal pain threshold,17 which has been
verified in our experiment. Thermal pain threshold in
the capazepine group was close to it in the control
group, indicating that capsazepine was incapable of in-
creasing the thermal pain threshold under the condi-
tion of non-activated TRPV1. The thermal pain thresh-
old in the MC group was significantly differentfrom it
in the control group; and it was significantly decreased
compared with the moxibustion group, indicating that
capsazepine might play the role of partial antagonism
against the analgesic effect of moxibustion. Research of
Jiyeon Kwak showed that hyperpolarization-activated
cation currents [I (h)] contributed to pain, particularly
in the generation of chronic neuropathic pain abnor-
malities. Capsaicin (1 µM) inhibited I (h), but the cap-
saicin-induced inhibition of I (h) was prevented by the
TRPV1 antagonist, capsazepine.23 The burning quality
of capsaicin-induced pain suggests that capsaicin and
heat might evoke painful responses through a common
molecular pathway,24 and for the reason, capsazepine
might be able to interdict the response caused by heat
as it interdicts capsaicin, which might be the reason for
lower thermal pain threshold in the MC group than it
in the moxibustion group.
TRPV1 is the target in controlling chronic and acute
pain and the key of analgesia.20,25 Studys found that cap-
saicin and other vanilloid receptors selectively activate
TRPV1 (nociceptive receptors) to desensitize it, pro-
moting the analgesic (therapeutic) effect of compounds
of capsaicin and other vanilloid receptors. Presented re-
peated TRPV1 agonists application to the skin produc-
es a degeneration of epidermal nerve fibers that may
underlie this type of analgesia.26 Schumacher M A had
revealed several overlapping and complementary mech-
anisms of capsaicin analgesia including receptor desen-
sitization, nociceptor dysfunction, neuropeptide deple-
tion, and nerve terminal destruction, where the de-
struction of nociceptor terminals may play the greatest
role in the effect of analgesia/treatment.21
In conclusion, moxibustion increasing thermal pain
threshold was correlative to TRPV1, and the increase
in Thermal pain threshold might be achieved via desen-
sitization of TRPV1 or damage of sensory terminals27
by the heat stimulations of moxibustion, where the
mechanism should be further explored. Without obvi-
ous side effects observed, moxibustion can be a safe in-
tervention for pain relief.
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